De novo malignant melanoma occurred in renal allograft: DNA typing to determine the origin of the tumour by Nemes, Balázs Áron et al.
Interventional Medicine & Applied Science, Vol. 2 (1), pp. 31–36 (2010) CASE REPORT
DOI: 10.1556/IMAS.2.2010.1.7
De novo malignant melanoma occurred
in renal allograft:
DNA typing to determine the origin
of the tumour
B. NEMES1*   É. TORONYI1   K. RAJCZY4   A. SZAKOS2  
B. SOMLAI3   A. DOROS1   R. CHMEL1   F. DERNER   L. KÓBORI1
1Transplantation and Surgical Clinic, Semmelweis University, Budapest, Hungary
21st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
3Dermatological Department, Semmelweis University Budapest, Hungary
4National Institute of Hematology and Immunology Budapest, Hungary
*Corresponding author: Balázs Nemes MD, PhD, Transplantation and Surgical Department, Semmelweis University,
Baross u. 23–25, H-1082 Budapest, Hungary; E-mail: nemes@trans.sote.hu
Abstract:Malignant diseases are considered as great challenges in clinical transplantation. It is well known that the incidence of malignancy is higher
in the transplanted population if compared with the normal population. It is important to distinguish between neoplastic diseases originating from
pre-existing lesions in the transplanted organs and de novo graft tumours. Post-transplant malignancy of donor origin is a rare complication of organ
transplantation, most likely transmitted as micrometastases within the parenchyma of the donor organ or from circulating tumour cells contained
within the organ. Malignant melanoma, although its incidence is rather low, is one of the most common donor-derived tumour inadvertently
transplanted, comprising 28% of donor transmitted tumours. Malignant melanoma in the graft without dermatological localisation is extremely rare.
We report a case of de novo melanoma occurring in the allograft, where transmission from the donor was excluded by DNA (desoxyribonucleic
acid) investigation. We did not find any data in the literature where a malignant melanoma occurred after transplantation in the transplanted kid-
ney without any skin lesions and the donor origin was excluded. We draw attention to the importance of the DNA typing in case of tumours oc-
curring in immunosuppressed patients.
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Introduction
Tumour development is an increasingly recognized prob-
lem in kidney transplanted patients. The incidence of ma-
lignancy in transplanted patients is higher than in the
general population. Since the development of immuno-
suppressive therapy transplanted patients live longer,
however, have greater chance to develop malignant dis-
eases. Length and intensity of immunosuppressive ther-
apy are related to the risk of post-transplant malignancy.
The risk of developing malignancy is 14% at 10 years and
40% at 20 years after transplantation [1, 2].
The leading cause of death in kidney transplant recip-
ients with a functioning graft are cardiovascular compli-
cations. Malignant tumours are the second most com-
mon cause of death after kidney transplantation [3, 4].
Malignant diseases are considered as great challenges in
clinical transplantation [5, 6]. Skin tumours are frequently
seen after organ transplantation, in particular, squamous
cell carcinoma. The incidence of malignant melanoma is
less extensively reviewed in the literature [7, 8].
In patients followed for 20 years after solid organ trans-
plantation post-transplant malignancies occurred in up to
50 %. Post-transplant malignancies are expected to be the
leading cause of death within the next 20 years in kidney
transplant recipients. Cancer will surpass cardiovascular
complications as the leading cause of death in transplant
patients within the next 2 decades. It is important to dis-
tinguish between neoplastic diseases originating from
pre-existing lesions in the transplanted organs and de
novo graft tumours. An understanding of the underlying
pathobiology and knowing how to minimize cancer risks
in transplant recipients are essential. The etiology of post-
transplant malignancy is believed to be multifactorial and
involves impaired immunosurveillance of neoplastic cells
as well as depressed antiviral immune activity with a num-
ber of common post-transplant malignancies being viral-
related. Although calcineurin inhibitors and azathioprine
have been linked with post-transplant malignancies,
newer agents such as mycophenolate mofetil and
sirolimus may even have antitumor properties [9, 10].
Long-term data evaluation is needed to determine
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whether the use of these agents will ultimately diminish
the mortality due to malignancy for transplant recipients.
Early diagnosis and management of de novo malignant
disease in transplant patients is crucial for the prognosis
of graft function and patients survival [11–15].
Post-transplant malignancy of donor origin is a rare
complication of organ transplantation, most likely trans-
mitted as micrometastases within the parenchyma of the
donor organ or from circulating tumour cells contained
within the organ. The incidence of tumour transmission
is reported to be 0.02–0.2%, with a mean time to diag-
nosis of 14.2 months [16–18]. Once a post-transplant
malignancy is diagnosed, differentation of the malignancy
is of recipient or donor derivation significantly influences
the treatment algorithm. In addition to the withdrawal
of immunosuppression, explantation and retransplanta-
tion may be the treatment protocol for donor transmit-
ted malignancies. Malignant melanoma is one of the most
common donor transmitted malignancy, comprising 28%
of donor transmitted tumours [19–21].
We report a case of kidney transplanted patient who
developed malignant melanoma in the transplanted kid-
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ney and the donor derived origin of tumour was excluded
by DNA HLA typing.
Case report
The 23-year-old male with end stage renale failure due
to focal segmental sclerosis was treated with regular
haemodialysis until 1997, when a cadaveric donor kidney
became available. The donor, a 45-year-old male had died
of a massive intracerebral haemorrhage. The donor had
no history or clinical evidence of melanoma or any other
tumour, as confirmed by the donor procedure. Autopsy
was not performed since no signs of malformation were
known at the time of the kidney transplantation. There
was a 1A, 1B and 1DR HLA (human leukocyte antigen)
antigen match between the donor and recipient. DNA
samples of the donor were stored (at minus 80 centigrade
in liquid nitrogen). Both the donor and the recipient
were CMV (cytomegalovirus) negative. The patient re-
ceived cyclosporine and steroid-based immunosuppres-
sion. The postoperative course was uneventful, there were
no rejection episodes and renal function was satisfactory
Fig. 1. CT scans of the patient, before and after chemotherapy CT scan of the minor pelvis (1.) with the tumourous kidney allograft in the
right iliac fossa before (1.) and after (2.) removal. White arrow shows the malignancy. CT scan of the thorax with bilateral pulmonal
metastases (3.), and a negative image after chemotherapy (4.). White arrows show the metastases
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(creatinine clearance of 80 ml/min) at discharge from
hospital (18 days after transplantation). Thirteen months
after the renal transplantation he was admitted to the hos-
pital because of fever and weight loss. Renal function was
unchanged; there were no signs of rejection. Ultra-
sonography of the graft showed a hyperdense, irregularly
shaped tumour, with a diameter of 10 centimetres. Chest
X-ray and CT (computer tomography) scan revealed mul-
tiple nodules, involving both lungs highly suspicious to
be metastatic in origin (Fig. 1). The biopsy of the kidney
graft showed a low-grade malignant mesenchymal tu-
mour. Immunosuppression was withdrawn and graftec-
tomy was planned. During the operation a large mass, in-
filtrating the whole kidney allograft, as well as the iliac
vessels, the ureter and the abdominal muscles was found.
The transplanted kidney was removed and a regional
block dissection of the inguinal lymph nodes were per-
formed. Regular haemodialysis was reinstituted.
Upon macroscopic inspection the graft kidney showed
several round foci of lobulated, partly necrotic tumour,
the largest measuring 105 mm in maximum dimension.
The tumour invaded the renal pelvis as well as other hilar
structures.
On microscopic examination an invasive solid tumour
could be identified (Figs 2 to 4). The cells showed re-
markable atypical characteristics with frequent mitotic fig-
ures, swollen nuclei, prominent eosinophilic nucleoli,
coarsely granulated chromatin pattern and occasionally
vacuolated cytoplasm. Scattered multinucleated giant
cells could also be demonstrated.
The immunohistochemistry was positive for vimetin,
S-100 protein (Fig. 3), CEA (carcinoembryonic anti-
gen), HMB-45 (Fig. 4) and was negative for LCA
(leukocyte common antigen), CD31, cytokeratin, EMA
(epithelial membran antigen), AFP (alpha fetoprotein)
and HCD. The examined lymph nodes showed the same
characteristics.
To determine whether the tumour was of donor- or re-
cipient origin DNA typing was performed on the re-
moved tumour and compared with the DNA of the
donor. DNA was obtained by trypsin digestion of the tu-
mour tissue followed by the salting-out method. DNA
typing was performed by PCR-SSP (sequence specific
primer) [22, 23] and the key-reactions were repeated by
the more sensitive nested PCR (polymerase chain reac-
tion) technique [24–26]. The result of DNA typing on
the basis of HLA mismatches excluded the donor origin
of the tumour. We concluded that the tumour repre-
sented a de novo malignancy and was not transmitted by
the donor (Fig. 5)
The patient received targeted oncological therapy:
dacarbazin (200 mg/m2) for 5 days (with 3 days inter-
ruptions) for 1 year. Control ultrasonography showed an
8-cm large recidive mass in the iliac fossa. On control
chest X-ray the pulmonary metastases disappeared. Re-
operation was performed: a local recurrence was found
De novo melanoma in a renal al lograft without cutaneous localisation
Fig. 2. HE staining, ×40 magnification. Black arrow shows the
melanoma, white arrow points to a glomeruli
Fig. 3. S-100 protein immunostaining. ×40 magnification. Dark
granules show positive staining for S-100 within all kidney
structures. Also a glomeruli can be identified
Fig. 4. HMB-45 staining ×40 magnification. Black arrow shows
the melanoma invading the kidney. The tumour showes typ-
ical positive immunostaining. The white arrow points to the
glomeruli
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and removed. Histology of the removed tissue and lymph
nodes did not reveal signs of malignancy. Reactive
changes in the lymph nodes and scar tissue with signs of
fibrosis were confirmed. The patient returned to regular
haemodialysis treatment, and following 6 (six) tumour-
free years after the transplantectomy and 5 (five) years
after completing the oncological therapy he was put on
the kidney transplant waiting list again. Ten years after
transplant nephrectomy he was transplanted with a ca-
daveric kidney with 1 HLA A, 2 HLA B and 1 HLA DR
matches. The donor was CMV positive and the recipient
CMV negative, so he received valganciclovir prophylaxis
for 3 months. The immunosuppressive therapy consisted
of Zenapax, Tacrolimus, Mycophenolate-mofetil and
steroids. On the 7th postoperative day clinical signs of re-
jection appeared, so the patient received steroid pulse
therapy for 5 consecutive days. His serum creatinine level
decreased.
Because of previous malignant melanoma his im-
munosuppressive therapy was converted to the combina-
tion of Sirolimus, Mycophenolate-mofetil and steroids 2
months after the transplantation. His kidney function is
stable, with a serum creatinine 112 µmol/l, GFR: 80
ml/min. The regular screening tests for malignancy did
not reveal any abnormalities.
Discussion
Tumour development is an increasingly recognized prob-
lem in kidney transplanted patients. The incidence of ma-
lignancy is higher in transplanted patients than in the
general population. Since the development of immuno-
suppressive therapy transplanted patients live longer,
however, have a greater chance to develop malignant dis-
eases. Length and intensity of immunosuppressive ther-
apy are related to the risk of post-transplant malignancy.
The risk of developing malignancy is 14% at 10 years and
40% at 20 years after transplantation.
The leading cause of death in kidney transplant recip-
ients with a functioning graft are cardiovascular compli-
cations. Malignant tumours are the second most com-
mon cause of death after kidney transplantation [27, 28].
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Fig. 5. Result of DNA typing of the tumour tissue. Agarose gel stained by ethidium bromide First row: results of DQB1 typing: positive reac-
tions are: 3, 4, 5, 7, which means DQB1*02,03 (patient’s type). Reaction 1 (DQB1* characteristic to the donor) is completely miss-
ing, even in more sensitive nested PCR (data not shown). Second row: DRB 1 typing results: 5, 6, 13, 16, 17, 22, which means
DRB1*03,11 and DRB3* (patient’s type). Donor specific reactions (4: DRB1*16 and 24: DRB%) are missing. The results of DNA
typing confirmed the origin of the tumour
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Immunosuppression has been identified as an etiologi-
cal factor in the increased incidence of malignancies in kid-
ney transplant recipients [28]. Immunosuppression has a
non-specific and a direct effect on tumour genesis. Non-
specific immunosuppression enhances oncogenic virus
replication. Steroids are believed not to be involved in
cancer development. Calcineurin inhibitors and azathio-
prin are relevant risk factors. Azathioprin reduces DNA
repair ability. Calcineurin inhibitors are involved through
various mechanisms in tumour development: They pro-
mote B-cell proliferation by increasing T lymphocyte IL-
6 secretion, decrease DNA repair ability. They also might
be able to promote the spreading of metastases by direct
cellular effect that is independent of their effect on the
host’s immune cells. Proliferation signal inhibitors are in-
volved in the control of cellular growth and proliferation.
Recent articles report that mTOR inhibitors have anti-
cancer effects as well as immunosuppressive properties. In
vitro and in vivo studies have documented the ability of
proliferation signal inhibitors to inhibit primary and
metastatic tumour growth, to stop the cell cycle in G1
phase. They decrease the expression of vascular endothe-
lial growth factor (VEGF-A) and the IGF-b expression.
The incidence of different tumours varies in different
geographical regions [29, 30]. Existing studies are not in
agreement over the increased risk of melanoma in the
transplanted population. Hollenbeak et al. showed that
renal transplantation recipients were nearly 3.6 times
more likely to develop melanoma than the general pop-
ulation, Le Mire et al. showed that in the studied Oxford
transplant population melanomas occurred at approxi-
mately 8 times the rate in the general population; this is
the highest rate reported in the literature [18, 31].
Considering the well-known aggressivity of melanomas
this is also an uncommon finding that after multidiscipli-
nary treatment (surgery, oncology) the patient became
tumour and metastasis free. Melanomas transmitted from
a donor were already reported [32, 33] and advanced
donor origin was proved by DNA typing as well [34, 35].
However, we did not find any report in the literature,
where a malignant melanoma occurred after transplanta-
tion without any skin lesion and the donor origin was ex-
cluded by DNA typing. We highlight the importance of
monitoring for de novo tumours in immunosuppressed
population, and also the role of DNA typing in the de-
termination of the tumour’s origin. In case of multior-
gan donation the importance of donor transmitted tu-
mours is even higher. Tumours have uncommon
behaviour in immunosuppressed patients. To achieve
good prognosis multidisciplinary treatment is suggested.
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